Equities analysts forecast that Kadmon Co. (NYSE:KDMN) will report earnings per share (EPS) of ($0.25) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Kadmon’s earnings. The lowest EPS estimate is ($0.26) and the highest is ($0.23). Kadmon reported earnings per share of ($0.39) during the same quarter last year, which would suggest a positive year-over-year growth rate of 35.9%. The company is expected to report its next quarterly earnings report on Monday, May 21st.
On average, analysts expect that Kadmon will report full-year earnings of ($1.11) per share for the current year, with EPS estimates ranging from ($1.25) to ($0.96). For the next year, analysts anticipate that the business will report earnings of ($0.91) per share, with EPS estimates ranging from ($1.29) to ($0.38). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that follow Kadmon.
Kadmon (NYSE:KDMN) last issued its quarterly earnings results on Tuesday, March 6th. The company reported ($0.24) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.36) by $0.12. The business had revenue of $1.50 million during the quarter, compared to the consensus estimate of $3.07 million. The business’s quarterly revenue was down 65.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.50) earnings per share.
KDMN has been the topic of several recent research reports. Zacks Investment Research lowered Kadmon from a “hold” rating to a “sell” rating in a report on Wednesday, January 31st. Jefferies Group lifted their price objective on Kadmon to $16.00 and gave the stock a “buy” rating in a report on Tuesday, February 13th. Piper Jaffray reissued a “positive” rating and set a $9.00 price objective (up previously from $7.00) on shares of Kadmon in a report on Tuesday, February 13th. Finally, HC Wainwright reissued a “buy” rating and set a $25.00 price objective on shares of Kadmon in a report on Friday, March 9th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $11.45.
NYSE KDMN traded down $0.08 during trading on Friday, hitting $4.29. The company’s stock had a trading volume of 184,684 shares, compared to its average volume of 924,367. The company has a market cap of $331.88, a P/E ratio of -3.09 and a beta of 3.97. Kadmon has a 52 week low of $2.05 and a 52 week high of $5.86.
A number of hedge funds have recently made changes to their positions in KDMN. Goldentree Asset Management LP boosted its stake in Kadmon by 673.6% in the 4th quarter. Goldentree Asset Management LP now owns 1,611,730 shares of the company’s stock valued at $5,834,000 after buying an additional 1,403,397 shares in the last quarter. Crestline Management LP acquired a new stake in Kadmon in the 3rd quarter valued at $2,011,000. Susquehanna International Group LLP boosted its stake in Kadmon by 3,211.2% in the 3rd quarter. Susquehanna International Group LLP now owns 443,135 shares of the company’s stock valued at $1,485,000 after buying an additional 429,752 shares in the last quarter. Geode Capital Management LLC boosted its stake in Kadmon by 172.4% in the 4th quarter. Geode Capital Management LLC now owns 463,844 shares of the company’s stock valued at $1,679,000 after buying an additional 293,569 shares in the last quarter. Finally, Spark Investment Management LLC acquired a new stake in Kadmon in the 4th quarter valued at $868,000. 61.71% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This story was first published by Macon Daily and is owned by of Macon Daily. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://macondaily.com/2018/04/12/kadmon-co-kdmn-expected-to-post-earnings-of-0-25-per-share.html.
Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics within autoimmune and fibrotic, oncology, and genetic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including those indicated for the management of rare diseases.
Get a free copy of the Zacks research report on Kadmon (KDMN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.